Cell Journal [Yakhteh]. 2017; 19 (Supp. 1): 55-65
em Inglês
| IMEMR
| ID: emr-189340
ABSTRACT
Objective:
In this study we prepared a novel formulation of liposomal doxorubicin [L-DOX]. The drug dose was optimized by analyses of cellular uptake and cell viability of osteosarcoma [OS] cell lines upon exposure to nanoliposomes that contained varying DOX concentrations. We intended to reduce the cytotoxicity of DOX and improve characteristics of the nanosystems
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Polietilenoglicóis
/
Osteossarcoma
/
Linhagem Celular
/
Sistemas de Liberação de Medicamentos
/
Linhagem Celular Tumoral
Limite:
Humanos
Idioma:
Inglês
Revista:
Cell J. [Yakhteh]
Ano de publicação:
2017
Similares
MEDLINE
...
LILACS
LIS